Schizophrenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Schizophrenia Pipeline Drugs Market Report Overview
The symptoms of Schizophrenia include delusions, hallucinations, disorganized speech, and disorganized behavior. Risk factors include family history, age, drugs (psychoactive), and weakened immune system. Treatment includes antipsychotic medications.
The Schizophrenia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects.
Schizophrenia Pipeline Products Market Segmentation by Targets
The key targets in the Schizophrenia pipeline products market are D2 Dopamine Receptor, 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 1A, Muscarinic Acetylcholine Receptor M4, Muscarinic Acetylcholine Receptor M1, D3 Dopamine Receptor, 5-Hydroxytryptamine Receptor 2, 5-Hydroxytryptamine Receptor 7, Alpha 1B Adrenergic Receptor, cAMP and cAMP Inhibited cGMP 3′,5′ Cyclic Phosphodiesterase 10A, and others.
Schizophrenia Pipeline Products Market Analysis by Targets
For more target insights into the Schizophrenia pipeline products market, download a free report sample
Schizophrenia Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the Schizophrenia pipeline products market are 5-Hydroxytryptamine Receptor 2A Antagonist, D2 Dopamine Receptor Antagonist, 5-Hydroxytryptamine Receptor 1A Agonist, D2 Dopamine Receptor Agonist, Muscarinic Acetylcholine Receptor M4 Agonist, Muscarinic Acetylcholine Receptor M1 Agonist, 5-Hydroxytryptamine Receptor 2 Antagonist, D3 Dopamine Receptor Agonist, 5-Hydroxytryptamine Receptor 7 Antagonist, Alpha 1B Adrenergic Receptor Antagonist, and others.
Schizophrenia Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights into the Schizophrenia pipeline products market, download a free report sample
Schizophrenia Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the Schizophrenia pipeline products market are oral, intramuscular, parenteral, subcutaneous, intravenous, sublingual, nasal, inhalational, and transdermal.
Schizophrenia Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the Schizophrenia pipeline products market, download a free report sample
Schizophrenia Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the Schizophrenia pipeline products market are small molecule, synthetic peptide, monoclonal antibody, cell therapy, and gene-modified cell therapy.
Schizophrenia Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the Schizophrenia pipeline products market, download a free report sample
Competitive Landscape
Some of the leading players in the Schizophrenia pipeline products market are Omeros Corp, Cerevel Therapeutics Holdings Inc, Luye Pharma Group Ltd, Intra-Cellular Therapies Inc, NeuroSolis Inc, Otsuka Pharmaceutical Co Ltd, Acadia Pharmaceuticals Inc, Autifony Therapeutics Ltd, Bristol-Myers Squibb Co, and MedinCell SA.
Schizophrenia Pipeline Products Market Analysis by Players
To know more about the leading players in the Schizophrenia pipeline products market, download a free report sample
Schizophrenia Pipeline Products Market Report Overview
Key Targets | D2 Dopamine Receptor, 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 1A, Muscarinic Acetylcholine Receptor M4, Muscarinic Acetylcholine Receptor M1, D3 Dopamine Receptor, 5-Hydroxytryptamine Receptor 2, 5-Hydroxytryptamine Receptor 7, Alpha 1B Adrenergic Receptor, cAMP and cAMP Inhibited cGMP 3′,5′ Cyclic Phosphodiesterase 10A, and Others |
Key Mechanisms of Action | 5-Hydroxytryptamine Receptor 2A Antagonist, D2 Dopamine Receptor Antagonist, 5-Hydroxytryptamine Receptor 1A Agonist, D2 Dopamine Receptor Agonist, Muscarinic Acetylcholine Receptor M4 Agonist, Muscarinic Acetylcholine Receptor M1 Agonist, 5-Hydroxytryptamine Receptor 2 Antagonist, D3 Dopamine Receptor Agonist, 5-Hydroxytryptamine Receptor 7 Antagonist, Alpha 1B Adrenergic Receptor Antagonist, and Others |
Key Routes of Administration | Oral, Intramuscular, Parenteral, Subcutaneous, Intravenous, Sublingual, Nasal, Inhalational, and Transdermal |
Key Molecule Type | Small Molecule, Synthetic Peptide, Monoclonal Antibody, Cell Therapy, and Gene-Modified Cell Therapy |
Leading Players | Omeros Corp, Cerevel Therapeutics Holdings Inc, Luye Pharma Group Ltd, Intra-Cellular Therapies Inc, NeuroSolis Inc, Otsuka Pharmaceutical Co Ltd, Acadia Pharmaceuticals Inc, Autifony Therapeutics Ltd, Bristol-Myers Squibb Co, and MedinCell SA |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
AbbVie Inc
Acadia Pharmaceuticals Inc
Adamed Pharma SA
Adare Pharma Solutions
Addex Therapeutics Ltd
AgeneBio Inc
AgoneX Biopharmaceuticals Inc
Alexza Pharmaceuticals Inc
Ananda Scientific Inc
Anavex Life Sciences Corp
Athira Pharma Inc
Autifony Therapeutics Ltd
Avanir Pharmaceuticals Inc
Avicanna Inc
BCWorld Pharm Co Ltd
Benuvia Therapeutics Inc
Biogen Inc
BioXcel Therapeutics Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Celon Pharma SA
Cerevance Inc
Cerevel Therapeutics Holdings Inc
Curemark LLC
CuroNZ Ltd
Cyclerion Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Daya Drug Discoveries Inc
Delpor Inc
Denovo Biopharma LLC
Echo Pharmaceuticals BV
Endosane Pharmaceuticals GmbH
Entheogenix Biosciences Inc
Exscientia Plc
F. Hoffmann-La Roche Ltd
Gabather AB
Gedeon Richter Plc
Genochem SAS
GP Pharm SA
H. Lundbeck AS
Intra-Cellular Therapies Inc
Io Therapeutics Inc
Jaguar Health Inc
Jazz Pharmaceuticals Plc
Jiangsu Enhua Pharmaceutical Group Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Nhwa Pharmaceutical Co Ltd
Johnson & Johnson
Karuna Therapeutics Inc
Laboratorios Farmaceuticos Rovi SA
LB Pharmaceuticals Inc
Lead Discovery Center GmbH
Livzon Pharmaceutical Group Co Ltd
Lohocla Research Corp
Luye Pharma Group Ltd
Lyndra Therapeutics Inc.
Malachite Innovations Inc
MapLight therapeutics Inc
MedinCell SA
Mental-Heal Ltd
Merck & Co Inc
Midatech Pharma Plc
Mitsubishi Tanabe Pharma Corp
Nanomi BV
Neonc Technologies Inc
Neumora Therapeutics Inc
Neurelis Inc
Neurocrine Biosciences Inc
NeurOp Inc
NeuroSolis Inc
Newron Pharmaceuticals SpA
Nostrum Biodiscovery SL
Novartis AG
Omeros Corp
Oryzon Genomics SA
Otsuka Pharmaceutical Co Ltd
OWP Pharmaceuticals Inc
Pasithea Therapeutics Corp
ProMIS Neurosciences Inc
Ra Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
Saniona AB
Shanghai Pharmaceutical Group Co Ltd
Shanghai Zhongze Medicine Tech Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Siragen Pharmaceuticals Inc
Sirtsei Pharmaceuticals Inc
SkySea Pharmaceutical Inc
Sosei Group Corp
Sumitomo Pharma Co Ltd
Sunovion Pharmaceuticals Inc
Suven Life Sciences Ltd
SyneuRx International (Taiwan) Corp
Taho Pharmaceuticals Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Terran Biosciences Inc
Teva Pharmaceutical Industries Ltd
The Greater Cannabis Company Inc
Therapeutic Solutions International Inc
Valentec
Vanda Pharmaceuticals Inc
Verge Genomics
Vivozon Inc
Whan In Pharm Co Ltd
YaoPharma Co Ltd
Yoda Pharmaceuticals Inc
Zhejiang Jingxin Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Schizophrenia pipeline products market?
The key targets in the Schizophrenia pipeline products market are D2 Dopamine Receptor, 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 1A, Muscarinic Acetylcholine Receptor M4, Muscarinic Acetylcholine Receptor M1, D3 Dopamine Receptor, 5-Hydroxytryptamine Receptor 2, 5-Hydroxytryptamine Receptor 7, Alpha 1B Adrenergic Receptor, cAMP and cAMP Inhibited cGMP 3′,5′ Cyclic Phosphodiesterase 10A, and others.
-
What are the key mechanisms of action in the Schizophrenia pipeline products market?
The key mechanisms of action in the Schizophrenia pipeline products market are 5-Hydroxytryptamine Receptor 2A Antagonist, D2 Dopamine Receptor Antagonist, 5-Hydroxytryptamine Receptor 1A Agonist, D2 Dopamine Receptor Agonist, Muscarinic Acetylcholine Receptor M4 Agonist, Muscarinic Acetylcholine Receptor M1 Agonist, 5-Hydroxytryptamine Receptor 2 Antagonist, D3 Dopamine Receptor Agonist, 5-Hydroxytryptamine Receptor 7 Antagonist, Alpha 1B Adrenergic Receptor Antagonist, and others.
-
What are the key routes of administration in the Schizophrenia pipeline products market?
The key routes of administration in the Schizophrenia pipeline products market are oral, intramuscular, parenteral, subcutaneous, intravenous, sublingual, nasal, inhalational, and transdermal.
-
What are the key molecule types in the Schizophrenia pipeline products market?
The key molecule types in the Schizophrenia pipeline products market are small molecule, synthetic peptide, monoclonal antibody, cell therapy, and gene-modified cell therapy.
-
Who are the leading players in the Schizophrenia pipeline products market?
Some of the leading players in the Schizophrenia pipeline products market are Omeros Corp, Cerevel Therapeutics Holdings Inc, Luye Pharma Group Ltd, Intra-Cellular Therapies Inc, NeuroSolis Inc, Otsuka Pharmaceutical Co Ltd, Acadia Pharmaceuticals Inc, Autifony Therapeutics Ltd, Bristol-Myers Squibb Co, and MedinCell SA.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.